Substance
ID:278
Names and Identifiers
Synonyms
CarisoprodolIsoprothaneCarisoprodatumIsomeprobamateIsoprotaneCarisoprodate
IUPAC Traditional name
2-{[(isopropylcarbamoyl)oxy]methyl}-2-methylpentyl carbamate
IUPAC name
2-methyl-2-({[(propan-2-yl)carbamoyl]oxy}methyl)pentyl carbamate
Brand Name
CaridolinChinchenFlexagitMuslaxNeoticaFlexalMiorilFibrosonaSomaMiolisodalMioratrinaAtonalytListaflexScutamil-CCarisomaMioartrinaRelasomArusalSanomaArtifarFlexagiltFlexidonMeprodatFlexartalNospasmSkutamilSomanilApesan
Properties
Physical Property
Solubility
0.3 mg/ml
Hydrophobicity(logP)
2.1
Molecule Details
Drug Groups
approved
Description
A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1202)
Indication
For the relief of discomfort associated with acute, painful, musculoskeletal conditions.
Pharmacology
Carisoprodol is used as a skeletal muscle relaxant. One of its metabolites, meprobamate, is available as an anxiolytic agent.
Toxicity
Symptoms of overdose include drowsiness, giddiness, nausea, indigestion, or rash. Other adverse effects attributed to therapeutic use of carisoprodol include dizziness, irritability, insomnia, diplopia, temporary loss of vision, ataxia, weakness, headache, and dysarthria. Non-CNS adverse effects include gastrointestinal complaints, tachycardia, and postural hypotension. Patients sensitive to sulfites or tartrazine may experience wheezing, allergic rashes including erythema multiforme, or anaphylaxis after using some preparations of carisoprodol which contain such additives
Affected Organisms
Humans and other mammals
Biotransformation
Hepatic. Metabolized in the liver via the cytochrome P450 oxidase isozyme CYP2C19.
Half Life
8 hours
Protein Binding
60%
Elimination
Carisoprodol is eliminated by both renal and non-renal routes.
Clearance
* oral cl=0.772 L/hour/kg [Women]
* oral cl=0.38 L/hour/kg [Men]
* oral cl=0.38 L/hour/kg [Men]
References
•
Toth PP, Urtis J: Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clin Ther. 2004 Sep;26(9):1355-67.
[Pubmed]
•
Chou R, Peterson K, Helfand M: Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004 Aug;28(2):140-75.
[Pubmed]
•
Littrell RA, Hayes LR, Stillner V: Carisoprodol (Soma): a new and cautious perspective on an old agent. South Med J. 1993 Jul;86(7):753-6.
[Pubmed]
External Links
Molecular Spectra
No Data Available
Click here to submit data
References
• Chou R, Peterson K, Helfand M: Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004 Aug;28(2):140-75. Pubmed
• Toth PP, Urtis J: Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clin Ther. 2004 Sep;26(9):1355-67. Pubmed
• Littrell RA, Hayes LR, Stillner V: Carisoprodol (Soma): a new and cautious perspective on an old agent. South Med J. 1993 Jul;86(7):753-6. Pubmed